Best GLP-1 programs for menopause
Compare weight-management programs, monitoring and support in midlife.
Advertising disclosure. We earn commissions from some links, at no extra cost to you. How we’re funded
Programs scored for midlife
The featured partner is placed first; other positions include a partner boost. Scores are unchanged. Featured placements above are paid and separate.
- 89.8MidlifeView plan
1.CoreAge Rx
Featured partnerOverall Luna Fit 93/100
Semaglutide: Starting at $79/moTirzepatide: Starting at $129/moDetails & terms - 87.4MidlifeView plan
Overall Luna Fit 87/100
Medication prices & plan terms below.Details & terms - 86.4MidlifeView plan
Overall Luna Fit 86/100
Medication prices & plan terms below.Details & terms - 85MidlifeView plan
Overall Luna Fit 86/100
Medication prices & plan terms below.Details & terms - 85MidlifeView plan
Overall Luna Fit 85/100
Medication prices & plan terms below.Details & terms - 90.9MidlifeView plan
6.Allara Health
Highest scoreOverall Luna Fit 83/100
Medication prices & plan terms below.Details & terms - 84.7MidlifeView plan
Overall Luna Fit 83/100
Medication prices & plan terms below.Details & terms - 83.4MidlifeView plan
Overall Luna Fit 73/100
Medication prices & plan terms below.Details & terms - 83.2MidlifeView plan
Overall Luna Fit 83/100
Medication prices & plan terms below.Details & terms - 88.6MidlifeView plan
Overall Luna Fit 86/100
Medication prices & plan terms below.Details & terms
Full prices & plan conditions
Starting prices, introductory offers and prepaid equivalents describe different purchases. Read each provider’s full terms before comparing the amount you will pay.
Enhance MD
Semaglutide: $249 every 4 weeks month-to-month (13 charges a year); $212/mo only on the 12-month prepay
Tirzepatide: $329 every 4 weeks month-to-month (13 charges a year); $280/mo only on the 12-month prepay
Eden
Semaglutide: $99/mo at every dose (its terms describe a separate membership)
Tirzepatide: $129/mo at every dose (its terms describe a separate membership)
Found
Semaglutide: $289 every 4 weeks cash-pay ($179 first month); $199 with qualifying insurance ($99 first month), plus visit cost-sharing; $169 cash-pay equivalent on the 12-month commitment
Tirzepatide: $359 every 4 weeks cash-pay ($219 first month); $289 with qualifying insurance ($149 first month), plus visit cost-sharing; $239 cash-pay equivalent on the 12-month commitment
Sesame Care
Semaglutide: Brand Wegovy pill from $149/mo at 1.5 and 4 mg, $299/mo at 9 and 25 mg — plus Sesame care: $59/mo only on the 12-month prepay, otherwise $99 billed every 28 days (13 charges a year)
Tirzepatide: Brand Zepbound from $299/mo (vial: $299 at 2.5 mg, $399 at 5 mg, $449 at 7.5–15 mg; KwikPen: $499 at 7.5 mg, $699 at 10–15 mg) — plus Sesame care: $59/mo on the 12-month prepay, otherwise $99 per 28 days
Allara Health
Semaglutide: Not published per drug — brand Wegovy (pen or pill) and Ozempic are prescribed and billed through your pharmacy and insurance or paid out of pocket; its own compounded semaglutide is cash-only with no price shown before signup. Self-pay care membership is $149/mo month-to-month, medication billed separately; a weight-loss page quotes GLP-1 care from $154/mo for the first three months without naming the drug
Tirzepatide: Not published per drug — brand Zepbound (vial or pen) and Mounjaro are prescribed and billed through your pharmacy and insurance or paid out of pocket; its own compounded tirzepatide is cash-only with no price shown before signup. Self-pay care membership is $149/mo month-to-month, medication billed separately
Gala Health
Semaglutide: From $199/mo on a 3-month plan per FAQ; separate pages advertise $179/mo on a yearly subscription; brand Ozempic from $1,299/mo
Tirzepatide: From $199/mo per product FAQ; $179/mo advertised on a yearly subscription, with no complete month-to-month ladder
HumeCare+
Semaglutide: $199/mo advertised as ongoing on the dedicated semaglutide page; homepage welcome-credit framing differs, confirm renewal
Tirzepatide: Current tirzepatide-specific quote required; public $299 reference does not establish its renewal price
Shed
Semaglutide: $199/mo month-to-month ($159/mo on a 12-month plan)
Tirzepatide: $299/mo month-to-month ($239/mo on a 12-month plan)
Midi Health
Semaglutide: $165.90 per 4-week supply at 0.1–0.5 mg for its compounded "GLP-1" injectable (Midi does not name the molecule), $270.90 at 0.75–1.5 mg, $340 at 1.75–2 mg, $355 at 2.5 mg; sublingual $164–$275; shipping included, no membership fee. Visits billed separately ($250 first / $150 follow-up self-pay, or in-network insurance). Brand-name GLP-1s go to your own pharmacy at your insurance's price
Tirzepatide: $210 per 4-week supply at 1.25–2.5 mg for its compounded "Dual-Action GLP-1/GIP" injectable, $285 at 3.75–6.25 mg, $375 at 7.5–12.5 mg, $434 at 13.75–15 mg; sublingual $209–$460; shipping included, no membership fee. Visits billed separately ($250 first / $150 follow-up self-pay, or in-network insurance)
CoreAge Rx is a featured partner and appears first. The highest Menopause Fit score belongs to Allara Health at 90.9. Neighboring scores are close across the 56.4–90.9 range.
The shortlist, in order
Each entry shows its Menopause Fit score and the overall Luna Fit Score beside it, so a strong general program with a weaker midlife fit — or the reverse — is visible rather than buried.
- 1.
CoreAge Rx
Featured partnerMenopause Fit
89.8/100
Overall Luna Fit
93/100Compounded semaglutide and tirzepatide on one account, at one posted price that does not rise with your dose — tirzepatide being the option many women with insulin resistance ask about.
- Semaglutide
- Starting at $79/mo
- Tirzepatide
- Starting at $129/mo
- Coverage
- US only; some state limits shown at intake (no list published)
- Brand-name access
- Compounded only
- 2.
Enhance MD
Menopause Fit
87.4/100
Overall Luna Fit
87/100A compounded GLP-1 program built on lab work: a Quest panel (including thyroid) before anyone prescribes, repeated every six months, with every price rung posted and three named pharmacies.
- Semaglutide
- $249 every 4 weeks month-to-month (13 charges a year); $212/mo only on the 12-month prepay
- Tirzepatide
- $329 every 4 weeks month-to-month (13 charges a year); $280/mo only on the 12-month prepay
- Coverage
- Licensed in all 50; launched in 40 states and DC
- Brand-name access
- Compounded only
- 3.
Eden
Menopause Fit
86.4/100
Overall Luna Fit
86/100One posted price in every month and at every dose, $99 for semaglutide and $129 for tirzepatide, plus brand-name prescriptions; read its terms, which describe a separate membership.
- Semaglutide
- $99/mo at every dose (its terms describe a separate membership)
- Tirzepatide
- $129/mo at every dose (its terms describe a separate membership)
- Coverage
- All 50 states
- Brand-name access
- Yes
- 4.
Found
Menopause Fit
85/100
Overall Luna Fit
86/100Offers separate compounded, branded and non-GLP-1 care plans with insurance-supported or cash-pay appointments; its detailed terms price each molecule separately and bill every four weeks.
- Semaglutide
- $289 every 4 weeks cash-pay ($179 first month); $199 with qualifying insurance ($99 first month), plus visit cost-sharing; $169 cash-pay equivalent on the 12-month commitment
- Tirzepatide
- $359 every 4 weeks cash-pay ($219 first month); $289 with qualifying insurance ($149 first month), plus visit cost-sharing; $239 cash-pay equivalent on the 12-month commitment
- Coverage
- Treatment and insurance availability vary by state; confirm both on the selected plan
- Brand-name access
- Yes
- 5.
Sesame Care
Menopause Fit
85/100
Overall Luna Fit
85/100A national telehealth marketplace that prescribes only brand-name GLP-1s (Wegovy pen and pill, Zepbound, Foundayo) through a clinician you pick by name, with separate PCOS and menopause programs alongside.
- Semaglutide
- Brand Wegovy pill from $149/mo at 1.5 and 4 mg, $299/mo at 9 and 25 mg — plus Sesame care: $59/mo only on the 12-month prepay, otherwise $99 billed every 28 days (13 charges a year)
- Tirzepatide
- Brand Zepbound from $299/mo (vial: $299 at 2.5 mg, $399 at 5 mg, $449 at 7.5–15 mg; KwikPen: $499 at 7.5 mg, $699 at 10–15 mg) — plus Sesame care: $59/mo on the 12-month prepay, otherwise $99 per 28 days
- Coverage
- Nationwide marketplace
- Brand-name access
- Yes
What the Menopause Fit score measures
A weighted blend of three sub-scores already published on each ranked provider's review. Nothing new is invented for this page, and the weights were fixed before the scores were computed.
- 40%Clinical oversight & labs
- 30%PCOS & hormonal suitability
- 30%Ongoing support
Clinical oversight and labs carries the most weight because midlife is when thinking “it's just menopause” is most expensive. Thyroid disease is several times more common in women, ferritin can sit low enough to matter while a blood count reads normal, and both look like the transition from the outside. A program that measures is doing something a program that titrates cannot.
Hormonal suitability is the factor that asks whether the hormonal picture is handled at all, or routed around. Ongoing support is weighted because midlife weight is a multi-year problem and a program built for a twelve-week sprint answers a different question.
Price transparency, nationwide access and cancellation fairness are deliberately excluded. They matter — they are in the overall Luna Fit Score, shown beside every row — but they matter equally to every reader. Folding them in here would reproduce the general ranking and this page would have no reason to exist.
What the evidence actually says about the transition
The midlife metabolic shift is measurable, not imagined: across the menopause transition body composition moves toward more fat and less lean mass, and fat redistributes toward the abdomen even when the scale barely moves. Greendale et al., JCI Insight (2019) tracked exactly that through the SWAN cohort.
On whether these medicines still work: a study in postmenopausal women found weight-loss response to semaglutide was comparable whether or not they were using hormone therapy — Hurtado et al., Menopause (2024). A 2025 review in Current Opinion in Obstetrics & Gynecology summarizes the current evidence for GLP-1 use in perimenopausal and postmenopausal women, and Palacios et al., Climacteric (2024) covers obesity management in menopause more broadly.
None of that makes a GLP-1 a menopause treatment, and none of it substitutes for the hormone-therapy conversation — see The Menopause Society's 2023 nonhormone therapy position statement for how the non-hormonal options are weighed. Our perimenopause and menopause guide goes further, and the hair-loss differential covers one symptom this transition is routinely blamed for — and sometimes causes.
Frequently asked questions
Is a GLP-1 approved for menopause weight gain?
No. Semaglutide and tirzepatide are approved for type 2 diabetes and for weight management. Neither is approved for menopause, and no program on this page can change that. Prescribing one because weight became harder to manage through the transition is a clinical judgment about weight, not an approved menopause treatment.
Is a GLP-1 the same as hormone therapy?
No, and they are not substitutes. GLP-1 medicines act on appetite and insulin response; they do nothing for estrogen. Menopausal hormone therapy is a separate decision with its own risks and benefits. Some women use both, coordinated by a clinician — none of the programs ranked here should be assumed to prescribe hormone therapy.
How is this ranking ordered?
CoreAge Rx is a featured partner and is placed first. Below it, programs are ordered by Menopause Fit with a capped boost for partners, so partners may appear first. Every provider's real score is printed on its row, so you can see where the order and the numbers differ. We earn a commission when you start treatment through some links on this site, at no extra cost to you.
Does a GLP-1 work as well after menopause?
The trial populations included many midlife and postmenopausal women and still showed substantial average weight loss. One study in postmenopausal women found comparable semaglutide response whether or not they were using hormone therapy. Menopause shifts the metabolic baseline; it does not switch the medicines off.
What should I ask a provider about, specifically for the transition?
Whether they check thyroid and metabolic markers rather than only weight, whether they will coordinate with whoever manages your hormone therapy, what happens to lean mass at your rate of loss, and what the plan looks like in year two — midlife weight is a long problem, not a twelve-week one.
Pricing, coverage and verification facts reflect each provider's public disclosures at last review; Menopause Fit and the Luna Fit Score are our editorial judgment per the methodology. Prices change — confirm on the provider's site. Informational only, and not medical advice. Canonical: https://lunametabolic.com/best/glp1-for-menopause
For a cost-first comparison, our month-to-month GLP-1 guide keeps ongoing injection prices separate from starting offers. If you prefer an FDA-approved product, explore programs with a brand-name medication pathway; availability and coverage still need to be confirmed.
Our provider recommendation hub explains which comparison suits each decision.
Looking more broadly? Compare GLP-1 programs for women, or read our menopause and GLP-1 evidence guide.